Incyte Corporation (INCY) stock: Winston Score, insiders and Congress trades

Incyte Corporation is a biotechnology company that discovers and sells medicines for serious diseases, mainly blood cancers and inflammatory conditions. Its most important product is Jakafi (ruxolitinib), a pill used to treat certain bone marrow diseases and a dangerous immune reaction called graft-versus-host disease. Incyte also sells Opzelura, a cream for skin conditions like vitiligo and atopic dermatitis, and earns royalties from partnering with larger drugmakers like Novartis. Incyte makes money primarily through drug sales and royalty payments from its partners. It operates mainly in the United States, though it has a growing presence in Europe, and its roughly $24 billion market value reflects strong profitability with operating margins above 30%. The company's main competitive advantage is its portfolio of approved drugs and deep pipeline of clinical-stage candidates, but its biggest risk is Jakafi's U.S. patent protection expiring around 2028, which could allow cheaper generic versions to enter the market and significantly cut revenue.

Editorial rules set and reviewed by Felix Prehn, Economist and Editor. Figures are refreshed daily from Financial Modeling Prep and company filings; last refreshed 2026-10-07.